Jefferies' Michael Yee breaks down 'Covid stock fatigue', biopharma investing in 2022 and more

view original post


Michael Yee, managing director covering healthcare equity research at Jefferies, joins CNBC’s ‘Squawk Box’ to discuss shares of Covid-19 drugmakers. Yee breaks down how investors can play shares in the pandemic heavyweights, such as Pfizer and Moderna, in 2022. “I think there absolutely is a vaccine or Covid stock fatigue that is starting off the year,” Yee tells CNBC.


23 minutes ago